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John V. Moran2,3,*Thank you, Haig, for the poignant introduction and kind
words. I would also like to thank Jeff Murray, The American
Society of Human Genetics (ASHG), the members of the
Awards Committee, and especially Christopher Pearson.
I first learned that I was the recipient of the 2013 Curt Stern
Award from Christopher when I was on vacation with my
family in San Francisco. I was pleasantly surprised and,
frankly, was rendered speechless. For those of you who
know me, you probably know that it takes a lot to render
me speechless. I am truly honored and humbled to be
the recipient of this prestigious honor.
As Haig so elegantly outlined, Curt Stern was an
outstanding scientist who conducted genetic studies in
model organisms to gain fundamental insights about
basic cellular processes. Namely, he used the fruit fly,
Drosophila melanogaster, to demonstrate crossing-over
between homologous chromosomes1 shortly after Harriet1This article is based on the address given by the author at themeeting of The A
MA, USA. The audio of the original address can be found at the ASHG website
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McClintock, demonstrated the same phenomenon in
maize.2 Stern subsequently demonstrated that mitotic
recombination could lead to the generation of somatic
mosaics,3 which is a topic that I will touch upon later in
the talk. In addition to being an outstanding basic scien-
tist, Curt Stern was also a fabulous educator. During my
career, I have found that excellent communication skills
and the ability to do outstanding basic science research
often go hand in hand.
While preparing this talk, I asked Tom Glover, my
neighbor in the Department of Human Genetics at the
University of Michigan, some questions about Curt Stern’s
career. Tom shared with me his copy of the third edition of
Curt Stern’s seminal textbook,4 Principles of Human
Genetics. He pulled the text off his bookshelf, gave it to
me, and then took it back. Tom paged through the text
while recounting how he used it during graduate school.
Nostalgically, Tom repeatedly told me what Stern’s
textbook meant to him and how influential it was to a
generation of human geneticists. I never met Curt Stern,
but it was touching to hear Tom talk about him so fondly.
It clearly put this award in context.
Over the years, my laboratory has studied what many
probably still consider to be ‘‘junk’’ DNA. However,
through the work of pioneers in the field, such as Maxine
Singer and Haig Kazazian, and the subsequent completion
of the human genome reference sequence, it is now
evident that our genomes are replete with sequences
derived from ‘‘jumping genes’’ known as transposable
elements.5 Indeed, long interspersed element 1 (LINE-1
or L1) retrotransposons and short interspersed elements
(such as Alu), which are sequences mobilized by the
LINE-1-encoded proteins, comprise approximately one
billion bases, or almost one-third, of human genomic
DNA (reviewed in Beck et al.6). A major tenet of our labo-
ratory is that a fundamental understanding of LINE-1
biology is necessary for elucidating the forces that have
shaped the structure, evolution, and perhaps function of
the human genome. Over the past 15 years, my laboratory
has focused on answering three basic scientific questions:
(1) How do LINE-1 retrotransposons mobilize (i.e., retro-
transpose) to new genomic locations? (2) What is themerican Society of HumanGenetics (ASHG) onOctober 26, 2013, in Boston,
.
atherine Street, University of Michigan Medical School, Ann Arbor,
y of Human Genetics. All rights reserved.
, 2014
impact of LINE-1 retrotransposition on the human
genome? (3) What host factors regulate and/or restrict
human LINE-1 retrotransposition?
Today, I would briefly like to discuss my scientific
journey by building upon themes discussed earlier at this
meeting in wonderful talks by Jeff Murray, Jessica Davis,
Kurt and Rochelle Hirschhorn, and Aravinda Chakravarti.
In particular, I would like to emphasize (1) the importance
of mentors, (2) the importance of picking an interesting
problem to study—emphasizing the idea that beauty is in
the eye of the beholder—and (3) the importance of a
supportive scientific environment. I have been fortunate
to have outstanding mentors throughout my career and
have benefitted tremendously from the scientific environ-
ments that they created in their laboratories. I continually
try to provide those same opportunities for my trainees—
honoring my previous mentors by ‘‘paying it forward.’’
I originally became interested in studying transposable
elements after reading a 1985 Cell paper, entitled ‘‘Ty
Elements Transpose through an RNA Intermediate,’’ by
Jef Boeke.7 In brief, the baker’s yeast, Saccharomyces
cerevisiae, harbors a class of retrotransposons known as
Ty elements, which structurally resemble retroviruses.
However, because Ty elements lack an envelope gene
that is required for exiting the cell, they are relegated to a
fate of intracellular replication. Through a series of well-
controlled, elegant genetic experiments, Jef designed an
assay to show that Ty elements could ‘‘jump’’ to new loca-
tions via an RNA intermediate—through a process known
as retrotransposition. He and his colleagues subsequently
used that assay in conjunction with molecular genetic,
genomic, and biochemical approaches to gain a detailed
understanding of Ty retrotransposition. Early in my
graduate career at The Ohio State University, Jef gave a
seminar detailing his scientific findings. Afterward, he
and two of my colleagues went out for dinner, drank
some beer, and discussed his research in depth. It was
then that I realized I wanted to pursue transposable-
element research. Jef is kind and gracious; he has served
as a mentor, colleague, and friend over the years—I am
thankful for his camaraderie.
My path to graduate school was somewhat indirect. I
graduated from Rochester Institute of Technology (RIT)
in 1986 with high honors in chemistry. I had applied to
various medical schools in New York State but was not
granted admission. So, late in the season, I needed an
alternative plan and began to look at graduate schools
throughout the country. However, the application dead-
lines had passed at many schools. Fortunately, I was
accepted into The Ohio State University Biochemistry Pro-
gram (OSBP).
My initial plan at Ohio State was to focus on biochemical
research. One of the requirements of OSBP was to take a
course in genetics or molecular genetics to help broaden
one’s academic knowledge base. Thus, I enrolled in a grad-
uate-level molecular genetics course. In the introductory
lecture, the instructor, Dr. Philip (Phil) Perlman, gave theThe Ameclass a list of approximately 50 genetic and molecular
genetic terms and said (I paraphrase), ‘‘If you don’t know
most of these terms, you may not do well in the course.’’
I only knew a few terms—actually, I knew one fewer than
I thought because I thought a library was a place where
you withdrew books. I spoke with Phil after the class. He
assured me that I would benefit from taking the course
and would do well if I worked hard.
Phil was an outstanding lecturer and teacher. I did well
in his course and subsequently approached him about con-
ducting a research rotation. We talked about the genetic
research being conducted in his laboratory, and it became
evident that my knowledge of some basic concepts (e.g.,
mitochondrial genetics, genetic mapping, and crossing-
over) was lacking. Phil also talked to me about a project
on intron splicing. Having completed my undergraduate
degree in chemistry, I understood that splicing occurred
by a two-step trans-esterification reaction, which I guess
impressed Phil because he generously allowed me to
conduct a research rotation. My initial projects focused
on genetic mapping and the characterization of respira-
tory-deficient mutants in yeast mitochondrial DNA. I liked
genetics, took to it quickly, and later was a teaching assis-
tant for an upper-level undergraduate genetics class. In a
theme that repeated during my graduate and postgraduate
studies, Phil, like a transposable element, moved to the
University of Texas Southwestern Medical Center (UTSW)
in Dallas. I completed my Master’s degree at Ohio State
and then moved with Phil to UTSW to complete my
doctoral studies, which focused on characterizing mobile
introns in yeast mitochondrial DNA.
When I entered graduate school, it was widely thought
that introns were ‘‘junk’’ RNA. Simply stated, introns repre-
sented sequences that needed to be removed or spliced
from premessenger RNAs to produce protein-coding
messenger RNAs. However, through the work of pioneers
in the field, including Tom Cech, Alan Lambowitz, Piotr
Slonimski, Bernard Dujon, Marlene Belfort, Ron Butow,
and Phil Perlman, it became apparent that certain introns,
as well as other cellular RNAs, could function as enzymes—
a discovery that allowed TomCech to share the 1989Nobel
Prize in Chemistry with Sidney Altman.8 Moreover, it
was found that some fungal mitochondrial introns encode
proteins and that some of those proteins catalyze intron
splicing and/or intron mobility.9,10 Indeed, certain fungal
mitochondrial introns were found to be mobile genetic
elements! The above vignette proved illustrative in my
career because it provided a direct example of how one’s
misperception of ‘‘junk’’ can change with dedicated efforts
and outstanding experimentation.
I had the good fortune in Phil’s laboratory to be an
author on a number of papers that focused on elucidating
mechanistic features of intron mobility in yeast mito-
chondria.11–14 Through trial and error, I also learned about
the art of experimental design, the importance of con-
ducting well-controlled experiments, and how to critically
analyze and interpret data. I still frequently relay one ofrican Journal of Human Genetics 94, 340–348, March 6, 2014 341
Figure 1. A Schematic of the LINE-1 Retrotransposition Assay
A full-length LINE-1 contains 50 and 30 UTRs (gray rectangles). The
50 UTR contains promoter activity (gray arrow). The two open
reading frames, ORF1 and ORF2, are depicted by maize and blue
rectangles, respectively. A polyadenlyation signal (red lollipop) is
present at the 30 end of the LINE-1 construct. The LINE-1 30 UTR
is disrupted by a NEO retrotransposition indicator cassette. The
cassette comprises a backward copy of a NEO expression cassette
that contains its own promoter (black arrow) and polyadenylation
signal (blue lollipop). NEO is also interrupted by an intron (SD,
splice donor site; SA, splice acceptor site) in the same transcrip-
tional orientation as the LINE-1. This arrangement ensures that
NEO expression can only be activated upon LINE-1 retrotransposi-
tion, allowing cells to subsequently grow in the presence of the
drug G418. The rationale of the assay and other details are pro-
vided in the text. This figure was adapted from Moran et al.20Phil’s mantras, ‘‘Trust your data,’’ to my trainees. I learned
many life-long lessons from Phil and will always be
thankful for his mentorship, time, and patience.
While I was in graduate school, Phil told me about the
seminal work being conducted on human LINE-1 elements
in Haig Kazazian’s laboratory at the Johns Hopkins School
of Medicine. I had the pleasure of seeing Haig present the
findings from his laboratory during a seminar at Ohio
State. As was the case for intronic RNA, it was thought
that much of the human genome consisted of ‘‘junk’’
DNA, that much of the ‘‘junk’’ was derived from trans-
posable elements that had lost the ability to move, and
that these transposable element sequences could simply
be considered molecular fossils.
The prevailing view that LINE-1 elements were simply
‘‘junk’’ DNA radically changed in 1988. In a seminal paper,
Haig screened for mutations within a cohort of 240 young
boys afflicted with the X-linked recessive disorder hemo-
philia A.15 He identified two patients who contained inde-
pendent de novo LINE-1 retrotransposition events in exon
14 of F8. These data unequivocally demonstrated that
LINE-1 retrotransposition could lead to sporadic cases of
human disease. Through a series of elegant, landmark
experiments, Beth Dombroski, a talented postdoctoral
researcher in Haig’s laboratory, subsequently identified a
full-length LINE-1 element that most likely spawned the
mutagenic LINE-1 insertion in one of the hemophiliac
patients.16 Thus, Haig’s lab was armed with the tools
needed to study human LINE-1 retrotransposition.342 The American Journal of Human Genetics 94, 340–348, March 6Because the reverse-transcriptase proteins encoded by
group II introns (which I studied in graduate school) and
human LINE-1s are evolutionarily related, I thought that
pursuing postdoctoral studies with Haig would both repre-
sent a natural extension of my graduate work and provide
me with a foray into human genetic research. After a slight
delay in completing my graduate studies, I moved to Johns
Hopkins in 1994. In a classic case of ‘‘ignorance is bliss,’’ I
only knew Haig (I subsequently dubbed him ‘‘The Big
Guy’’) from his LINE-1 work. I did not know that he had
high standing in the field of human genetics!
Almost immediately after my arrival, Haig transposed to
Philadelphia to become the chair of the Department of
Genetics at the University of Pennsylvania School of Medi-
cine. Like a mobile element, I commuted back and forth
between Baltimore and Philadelphia (and squatted for a
while in Jef Boeke’s laboratory) until my wife, Robin, was
able to arrange a transfer of her job at the Environmental
Protection Agency fromWashington D.C. to Philadelphia.
My time in Haig’s laboratory was wonderful. Haig always
answered my many, many questions and continually
taught me the history of human genetics throughout my
postdoctoral fellowship. In return, I brought experience
from Phil’s laboratory, which allowed me to develop a
genetic assay to study LINE-1 biology. Simply stated,
Haig has been an exceptional mentor and friend
throughout the years.
To design an assay for LINE-1 retrotransposition, we
borrowed genetic tricks originally developed by Thierry
Heidmann and Joan Curcio.17,18 In brief, I tagged the 30
UTR of a full-length LINE-1 with a retrotransposition
indicator cassette that we had obtained from Dixie
Mager.19 The cassette consisted of a backward copy of
neomycin phosphotransferase (NEO) equipped with its
own promoter and polyadenylation signal (Figure 1).
NEO was also interrupted by an intron, which is in the
same transcriptional orientation as the LINE-1 element.
The rationale of the experiment was as follows. If tran-
scription is initiated from the promoter driving NEO
expression, the intron cannot be spliced because it is in
the wrong polarity. However, if transcription is initiated
from either the native LINE-1 promoter or a heterologous
RNA polymerase II promoter driving LINE-1 transcrip-
tion, the intron can be spliced from LINE-1 RNA. Transla-
tion of the resultant LINE-1 mRNA would then allow the
production of LINE-1-encoded proteins (ORF1p and
ORF2p); NEO would not be translated from the LINE-1
mRNA because it was present in a ‘‘backward’’ orienta-
tion. However, if the LINE-1 mRNA retrotransposed—
that is, if it were reverse transcribed and integrated at a
new chromosomal location—NEO could become acti-
vated, allowing cells to grow in the presence of the NEO
analog, G418. In sum, our strategy allowed us to score
human LINE-1 retrotransposition events by simply count-
ing G418-resistant cells.
With the help of Roger Kennett, who taught me tissue
culture, we carried out our experimental assay (Figure 2)., 2014
Figure 2. Results from the LINE-1 Retrotransposition Assay
Top:Wild-type LINE-1 elements can readily retrotranspose in cells, whereas a deletionmutant and a reverse-transcriptasemutant cannot
retrotranspose. This figure was adapted from Moran et al.20
Bottom: The titles of papers published during my time in Haig Kazazian’s laboratory.To our surprise, we found that full-length LINE-1 con-
structs readily retrotransposed in cells.20 By comparison,
constructs that contained either a large deletion of
LINE-1 coding sequence or a missense substitution in the
LINE-1 ORF2p reverse-transcriptase active site were unable
to undergo retrotransposition. Subsequent experiments
revealed that the retrotransposition events derived from
our engineered constructs contained LINE-1 structural
hallmarks (e.g., they ended in a poly(A) tail, were 50 trun-
cated, and were flanked, in most cases, by target-site dupli-
cations) and uncovered additional functional domains
required for retrotransposition in both ORF1p and
ORF2p.20,21 Our results clearly demonstrated that the
LINE-1-encoded proteins are required for retrotransposi-
tion and, by analogy to work conducted on a related retro-
transposon in the silkworm, Bombyx mori, by Tom
Eickbush’s laboratory,22 suggested a plausible mechanism
for LINE-1 retrotransposition.
After developing this assay, we published a series of
papers (Figure 2) that helped decipher the mechanism of
L1 retrotransposition and its impact on the human
genome.20,21,23–25 Importantly, I came to the realization
that I could actually obtain gainful employment by study-
ing something that I really liked! I also realized that it
would be good to have a real job, with which my wife,
Robin, agreed, because my oldest son, Joshua, was born
in January of 1998.The AmeMy experience in Haig’s laboratory had a great influence
on my career, and I knew that I wanted to continue doing
human genetic research. Thus, in 1998, I accepted an assis-
tant professor position in the Department of Human
Genetics at the University of Michigan Medical School,
which was founded by Dr. James Neel. Notably, Jim trained
with Curt Stern during his time at the University of
Rochester,26 a fact that gives this award special meaning
to me.
During my time at Michigan, I have been fortunate to
have outstanding colleagues both inside and outside the
University. David Ginsburg and Tom Gelehrter originally
recruited me to Michigan. When I attended my first
Department of Human Genetics retreat, Tom had the fac-
ulty take a Myers-Briggs personality test. I learned that I
scored in an extroverted leadership quadrant. In contrast,
almost all the other faculty were diametrically opposed—
they scored in an introverted leadership quadrant. I
wondered, ‘‘My gosh, what did I get myself into’’? Upon
reflection, I can only imagine what everyone else was
thinking! I have been fortunate to have the full support
of both David and Tom over the years, and their enthu-
siasm was instrumental in allowing me to start my career
as an independent young scientist.
Others at Michigan have also served as mentors and
supported my growth as an independent scientist. Sally
Camper, my chair for the past 8 years, has been veryrican Journal of Human Genetics 94, 340–348, March 6, 2014 343
Figure 3. Pictures of My Laboratory over the Yearssupportive. Importantly, Sally successfully recruited a
number of outstanding young faculty members to the
department, reinvigorating the spirit of Human Genetics
at Michigan. I am pleased that she allowed me to run the
search committee for 2 of those years. Gil Omenn and
Martha Darling have been personally generous by endow-
ing a Department of HumanGenetics professorship, which
I have been fortunate to hold for the past 3 years. Finally, I
would like to acknowledge Miriam Meisler. Miriam has
directed the National Institutes of Health-funded Univer-
sity ofMichigan Genetics training program formany years.
I have served as the associate director of that program since
2006 and will assume the directorship in 2014. I thank
Miriam for her mentorship.
I have been fortunate to benefit from supportive environ-
ments in graduate school, as a postdoctoral fellow, and as a
facultymember. Thus, I realize the importance of creating a
supportive environment in my own laboratory. I have
never wanted a lab of 30þ people. Instead, I wanted to
create an environment that was large enough to reach
‘‘critical mass’’ but small enough that I could have a deep
understanding of the research in the laboratory. I have
always considered the lab a family andhave been extremely
fortunate to attract outstanding graduate and undergradu-
ate students, postdoctoral fellows, and research assistants
(Figure 3). Over the years, as in any family, my trainees
and I have seen each other at the best of times and theworst
of times. However, one of themost gratifying parts of being
a mentor is to see your trainees gain admission to graduate
or medical school, get outstanding postdoctoral fellowship
opportunities, and obtain independent faculty positions. I
am gratified that most of my trainees have been successful
in achieving their goals.344 The American Journal of Human Genetics 94, 340–348, March 6I am pleased that our laboratory has made several impor-
tant advances in understanding LINE-1 biology (Figures 4
and 5). On the mechanistic front, we followed up on pre-
vious studies by Gary Swergold27 and identified LINE-1 50
UTR sequences that were important for its trans-
cription.28 We further found that the second open reading
frame of LINE-1 mRNA is translated in an unconventional
manner29 and established a biochemical platform to both
detect and study the activities associated with the LINE-1-
encoded proteins.30–32
In genomics-based studies, we demonstrated that
LINE-1 is not simply an insertional mutagen but that
its retrotransposition could lead to alterations of target-
site genomic DNA.33,34 These include the generation
of intrachromosomal deletions via a single-strand-DNA-
annealing mechanism, as well as more baroque, complex
rearrangements that lead to small intrachromosomal
inversions by a synthesis-dependent strand-annealing
mechanism that, in certain aspects, resembles yeast
mating-type switching. Indeed, it was gratifying that
events we initially detected in cultured cells were also
detected at some frequency in the human genome. More-
over, in collaborative efforts with Richard Badge and
Evan Eichler, we have used modern genomic approaches
with our cell-culture assay to demonstrate that there
could be millions of retrotransposition-competent LINE-1
sequences in the extant human population.35
We serendipitously discovered an alternative, endonu-
clease-independent mechanism of LINE-1 retrotrans-
position, which suggests that LINE-1 sequences could
parasitize genomic lesions; this would essentially allow
for their repair through an RNA intermediate.36 Inter-
estingly, using cultured cell models, we found that, 2014
Figure 4. Representative Results Published from My Laboratory over the Years: The Mechanism of LINE-1 Retrotransposition
Top: A simplified working model for LINE-1 retrotransposition (reviewed in Beck et al.6). This figure is from Deanna Kulpa.
Bottom left: Results from a biochemical experiment show that ribonucleoprotein particles derived from cells transfected with a wild-type
engineered human LINE-1, an ORF1p RNA bindingmutant LINE-1, or an ORF2p endonucleasemutant LINE-1 contain reverse-transcrip-
tase activity, whereas an ORF2p reverse-transcriptase mutant does not. This figure was reprinted with permission from Kulpa and
Moran.30
Bottom right: An example of how LINE-1 retrotransposition can lead to structural variation in the human genome. This figure was
adapted with permission from Gilbert et al.33dysfunctional telomeres could also serve as substrates
for endonuclease-independent LINE-1 retrotransposition
events,37,38 thereby highlighting mechanistic similarities
between the catalytic subunit of telomerase and the
LINE-1 reverse transcriptase.
Finally, we demonstrated that LINE-1s could retrotrans-
pose in human embryonic stem cells.39 In collaborative
work with Fred (Rusty) Gage and Alysson Muotri, we
demonstrated that LINE-1 retrotransposition could lead
to somatic mosaicism in the brain.40,41 The extent to
which L1 retrotransposition affects the brain remains
somewhat controversial; however, these data harken back
to Curt Stern’s research and strongly suggest that tissue-
specific differences in LINE-1 retrotransposition could
lead to somatic mosaicism. Time will tell whether somatic
LINE-1 retrotransposition events in the brain represent a
type of ‘‘genomic noise’’ or whether they can sometimes
influence neuronal function.
Clearly, there has been an evolution of thought with
regard to LINE-1 elements in the human genome. BeforeThe AmeHaig’s studies, LINE-1s were mostly regarded as ‘‘junk’’
DNA. His seminal findings led to the idea that there might
be a number of active LINE-1 elements in the human
genome and that their mobility could occasionally lead
to disease. Now, we have come to the realization that active
LINE-1 elements, which are present at low or even private
allele frequencies, are alive and well in the human genome
and that their mobility continues to influence the evolu-
tion, structure, and perhaps function of the human
genome.
As with any field, there are several big questions that
remain in LINE-1 biology. These include the following:
(1) How often does LINE-1 retrotranspose? (2) When in
development does LINE-1 retrotranspose? (3) What cell
types accommodate LINE-1 retrotransposition? (4) Does
LINE-1 retrotransposition contribute to cancer? (5) How
does the host regulate and protect itself from unabated
LINE-1 retrotransposition? We, along with the rest of the
field, hope to get answers to these intriguing questions in
the coming years.rican Journal of Human Genetics 94, 340–348, March 6, 2014 345
Figure 5. Representative Results Published from My Laboratory over the Years: The Impact of LINE-1 Retrotransposition on the
Genome
Top left: Segregation of polymorphic LINE-1 elements in an extended pedigree. This figure was adapted from Badge et al.42
Top right: An image confirming that endonuclease-independent LINE-1 retrotranspositon can occur at dysfunctional telomeres in
Chinese hamster ovary cells that lack p53 activity and are deficient in a component of the nonhomologous-end-joining DNA-repair
machinery. This image was reprinted with permission from Morrish et al.37
Bottom left: The identification of active ‘‘hot L1s’’ from an individual genome.35
Bottom right: A human embryonic stem cell colony containing an engineered human LINE-1 retrotransposition event. This image was
reprinted with permission from Garcia-Perez et al.39To end, I would like to thank my family. Being half Irish
and pretty much half Finnish, I am an interesting genetic
mix—I have come to the conclusion that, for me, Irish is
dominant. I would like to thank my mother, who in her
quiet way has always been supportive of my education,
dreams, and ambitions—she is a wonderful person. My
father, who was a devout Catholic, taught me the values
ofhardwork and the importanceof an education.Hepassed
away in 2001 from complications associated with type II
diabetes. I applaud my ASHG colleagues, such as Mike
Boenhke, who activelyworks on understanding the genetic
etiology of type II diabetes—their efforts have special value
to me. I thank my brother, Craig, who is bigger, stronger,
and perhaps smarter than I am and has served as a New
York City police officer for 22 years. I have always admired
his honesty, hard work, and devotion to his family. Indeed,
many of my childhood friends became police officers or
held other public-sector jobs in New York City. I also thank
my grandmother, who in her straightforward, stoic Finnish346 The American Journal of Human Genetics 94, 340–348, March 6manner often asked (I paraphrase), ‘‘Why can’t you finally
get out of graduate school?’’
Finally, I must thank my beautiful wife, Robin. I met
Robin in 1986 only a few months before I graduated
from RIT. In a moment of clarity, I realized that she was
special and that I wanted to spend my life with her. Our
relationship involved quite a bit of transposition. We
commuted between Columbus and Rochester to visit
each other while I was in graduate school and then
between Dallas and Columbus after I moved to UTSW
with Phil. Although this took effort on both our parts, it
has worked out fabulously. We have three wonderful
children: Joshua, Jessica, and Ethan (Figure 6). It is a
blessing to have healthy children; watching them grow
has been one of the greatest pleasures of my life. Having
three kids and balancing two careers can be a challenge
at times. However, I would rather have an exciting, some-
times hectic life than a boring one. Simply stated, if it were
not for the unconditional love and support of Robin and, 2014
Figure 6. A Picture of Me, My Wife, Robin, and My Children,
Joshua, Jessica, and Ethan, at the Grand Canyonmy family, I would not have enjoyed the scientific success I
have had in my life. I am a lucky man. Thank you again for
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